Tag: genomics
-
FDA Approves Precision Solid Tumor Cancer Diagnostics
The Food and Drug Administration approved genomic tests for solid tumor cancers that identify the most promising available therapies matched to the tumor’s genetic mutations.
-
Protein Made by Synthetic Bacteria with Expanded DNA
An academic-industry lab team produced a synthetic protein from an engineered bacteria, with DNA modified to expand its number of chemical coding components.
-
Large-Scale Genome Editing Technology in Development
Two biotechnology companies are creating an automated process for delivering large, complex genetic cargoes into cells for genome editing.
-
Rapid DNA, RNA Capture Technique Devised
Researchers in Australia developed a simple and inexpensive dipstick technique that captures and purifies specimen samples for genetic analysis in about 30 seconds.
-
Genome Editing Enhances CAR T-Cells to Fight Cancer
A process using genome editing is shown to bolster cancer-fighting properties of T-cells from the immune system already modified to attack cancer cells.
-
Cancer Center, Analytics Company Partner on Precision Care
Memorial Sloan Kettering Cancer Center in New York is collaborating with health care analytics company Cota Inc. to offer more precise care strategies for patients.
-
New Finance, Development Model for Pancreatic Disease
An organization is being formed to adopt performance-based financing and precision medicine to accelerate research and development on pancreatitis.
-
FDA Sets Genetic Health Test Review Process
The U.S. Food and Drug Administration is proposing new review requirements for genetic tests of health risks that providers market directly to consumers.
-
RNA Meds Companies Partner on Human, Animal Vaccines
Synthetic Genomics Inc. and Arcturus Therapeutics Inc. are collaborating on longer-lasting and more robust RNA therapies and vaccines for humans and animals.
-
Fox Foundation, 23andMe in Large-Scale Parkinson’s Study
The Michael J. Fox Foundation and personal genetics company 23andMe are recruiting a large group of individuals with and without Parkinson’s disease to provide a more complete picture of the disorder.